IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation ("Nymox") (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella. The lawsuit is styled Nymox Pharmaceutical Corporation vs. AscellaHealth, LLC., case No. 30-2023-01362136-CU-BT-CJ. Nymox filed its lawsuit in California Superior Court, Orange County on November 8, 2023, to protect its shareholders' interests, as Nymox alleges that AscellaHealth, LLC ("Ascella") engaged in unlawful means in repeated attempts to gain control of Nymox for its own advantage, at what would have been at the expense of Nymox's shareholders.
The lawsuit contends the following:
- Ascella's conduct included using connections with (now-former) Nymox corporate officers and directors, including its General Counsel, to pass off an investment proposal as a way to gain access to highly confidential and proprietary company information, and to take control of the company's assets by a kick-back scheme.
- After this scheme was uncovered and thwarted, Ascella has continued relentlessly in its attempts to interfere with Nymox's relationship with its shareholders, including publishing confidential Nymox information using a front organization called "Committee to Restore Nymox Shareholder Value," and undertaking a failed attempt to organize a sham shareholder meeting to take control of Nymox.
Ascella presumably thought that Nymox would submit to or collapse under these coordinated assaults on its business, allowing Ascella to reap the years of Nymox's efforts to take its pipeline drugs including NYMOZARFEX to market.
Ascella did not count on the resiliency of Nymox's Management and Board, the loyalty of its shareholders and other stakeholders, and the strength of the justice system in both the United States and the Bahamas. Nymox is confident that it will be vindicated in court. Nymox has not been deterred from its core business mission of bringing life changing drugs to market and looks forward to continued success notwithstanding the bad acts of Ascella. The company will be seeking $250 million in compensatory and punitive damages.
About NYMOX
Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks, the discomforts of surgery, and BPH surgery has side effects such as permanent retrograde ejaculation for many patients.
Nymox recently reported 10-year follow-up new data on all available patients from its U.S. clinical trial of NYMOZARFEX for the treatment of low grade localized prostate cancer. The available long-term data newly assessed, confirmed that all available data shows that the NYMOZARFEX treatment had important and statistically significant benefit for reducing the long-term progression of these prostate cancers.
About NYMOZARFEX (Fexapotide)
NYMOZARFEX is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 NYMOZARFEX administrations. NYMOZARFEX has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2022, and its Quarterly Reports.
